Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Homogenous Dose Distribution

NCT00643994 is registered in ClinicalTrials.gov with Accuray Incorporated as lead sponsor.

NCT NCT00643994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00643994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Homogenous Dose Distribution
Lead sponsor
Accuray Incorporated
Phase
Not applicable
Overall status
Completed
Start date
December 31, 2007
Completion date
January 27, 2021
Enrollment
379 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate, prostate cancer, prostate neoplasms, prostatic cancer, prostatic neoplasms